Multi-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors Journal Article
| Authors: | Bang, A. S.; Fay, C. J.; LeBoeuf, N. R.; Etaee, F.; Leventhal, J. S.; Sibaud, V.; Arbesman, J.; Wang, J. Y.; Kwong, B. Y. |
| Article Title: | Multi-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors |
| Abstract: | Purpose: Cutaneous adverse effects from cyclin-dependent 4 and 6 kinase inhibitors (CDK4/6i) used in metastatic breast cancer are prevalent and well described. Vitiligo-like lesions have been reported and are rare. They can negatively impact patients’ quality of life and may be associated with survival benefits. We describe the clinical characteristics of vitiligo-like lesions in an international cohort of patients treated with CDK4/6i to help improve recognition and management. Methods: Retrospective review of patients diagnosed with vitiligo-like lesions from CDK4/6i from five academic institutions in the USA and Europe was performed. Ten patients were included in the study. Results: Median age of our patients was 55 (range 37–86). Median progression-free survival was 24 months in 5 patients. The median time to rash was 10 months. Sun-exposed areas such as the arms and face were the most affected areas. Multiple skin-directed therapies such as topicals, laser, and phototherapy were trialed with minor success. Mild repigmentation was seen in one patient treated with ruxolitinib cream. CDK4/6 treatment was discontinued due to the vitiligo-like lesions in one patient. Conclusion: Clinical characteristics are similar to previously reported findings in case reports and series. We add topical ruxolitinib as a potential treatment option for these patients and include data regarding progression-free survival that should continue to be collected. No definitive conclusions can be made regarding survival benefits from our cohort. Clinicians should refer these patients to dermatologists to aid with management. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024. |
| Keywords: | adult; clinical article; controlled study; human tissue; aged; middle aged; case report; drug safety; drug withdrawal; side effect; treatment duration; united states; cancer patient; follow up; demography; disease association; progression free survival; quality of life; breast cancer; skin biopsy; sun exposure; cohort analysis; retrospective study; pruritus; rash; pigmentation; europe; electronic medical record; multicenter study; dermatitis; cycline; drug therapy; tacrolimus; metastatic breast cancer; adverse drug reaction; therapy; cyclin dependent kinase 4; pimecrolimus; clobetasol; triamcinolone; laser therapy; cyclin dependent kinase 6; vitiligo; cutaneous parameters; cream; desonide; phototherapy; ruxolitinib; dermatologic adverse event; very elderly; human; male; female; article; palbociclib; abemaciclib; ribociclib; oncodermatology; cdk4/6 inhibitors; repigmentation; special situation for pharmacovigilance; vitiligo like; fitzpatrick ii; fitzpatrick iii; fitzpatrick iv; vitiligo like lesion |
| Journal Title: | Breast Cancer Research and Treatment |
| Volume: | 204 |
| Issue: | 3 |
| ISSN: | 0167-6806 |
| Publisher: | Springer |
| Date Published: | 2024-04-01 |
| Start Page: | 643 |
| End Page: | 647 |
| Language: | English |
| DOI: | 10.1007/s10549-023-07217-2 |
| PUBMED: | 38224427 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
